News

With the help of traceability, new feature prioritizes efficiency and safety, from production to patient.

Hoping to accelerate the drug delivery process, production is expected to begin as early as 2025.

Following numerous successful trial runs, vaccine production is expected to reach 700 million.

Expansion expected to increase global capacity by 75%.

Enhancements to help keep products frozen for over 144 hours, company says.

Joint venture revolves around around the use of raw materials for the development—and ultimately commercialization—of therapies.

New 25,000 square-foot facility will help grow customers’ gene therapy programs.

Site expected to support growth of advanced analytics and data science team.

Pharma sector, FMI report says, is quickly growing, due to globalization and development of low-cost medications.

Investment helps encourage sustainability in the space, especially as it pertains to pharma, company says.

cGMP line will fill vials, syringes, and cartridges, while supporting small-scale commercial production.

Conclusion driven by various factors, including product shortages and cost pressures.

Flights from Colombia and Ecuador more than doubled during the season, resulting in exports of nearly 18,000 tons.

South Korea facility expected to provide fill-finish capabilities.

New California plant expected to streamline medicine production.

Investment expected to establish additional cGMPs, expand CDMO services.

Meanwhile, PDG issues more DSCSA guidance on data interoperability.

Joint venture expected to address pharma’s injectable drug-filling sector.

Purchase doubles staffing, adds global capabilities.

Collaboration to support biotech company’s clinical and commercial production efforts.

Plant is expected to offer packaging, serialization, and third-party contract manufacturing services.

Global air freight market data suggests only a 1.6% demand drop off compared to 2019.

Saint-Beauzire complex dedicated to sterile liquid drug production.

The new $43M plasmid manufacturing facility will support both clinical and commercial production in the cancer and infectious disease spaces.

CDMO is commissioning third GMP biologics facility in Fremont.

CDMO will be providing high-quality lentiviral vectors for CAR-T therapies.

Location serves as the US flagship for company’s global pharma development network.

In effort to preserve medication, contribution will provide 150 refrigeration units across 17 countries.